Fennec Pharmaceuticals reported continued growth in demand for PEDMARK ® (sodium thiosulfate), its treatment designed to reduce the risk of hearing loss associated with cisplatin chemotherapy, as new clinical evidence adds support for protecting hearing without compromising cisplatin’s antitumor activity....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
PEDMARK (sodium thiosulfate) already holds FDA approval for cisplatin-related hearing protection in pediatric patients; audiologists working in oncology settings should be aware of growing utilization, but this blog post adds no new clinical guidance beyond the existing label.
Cisplatin-induced hearing loss (ototoxicity) is a significant survivorship issue in pediatric oncology, and expanding uptake of an FDA-approved protective agent could reduce the long-term audiological burden on this population.
- 01Fennec reports increasing demand for PEDMARK (sodium thiosulfate) for cisplatin-related hearing protection.
- 02New clinical data cited claim hearing protection without compromising chemotherapy efficacy.
- 03Content originates from a manufacturer-affiliated blog post, not a peer-reviewed source.
- 04PEDMARK is FDA-approved specifically for pediatric patients receiving cisplatin-based chemotherapy.
- 05Audiologists in pediatric oncology settings should monitor this space for emerging real-world evidence.
PEDMARK reduces cisplatin-associated hearing loss without compromising chemotherapy efficacy.
press releasepartially supportedDemand for PEDMARK is growing among prescribers.
press releaseunclear